However, cotreatment with CRY and the ferroptosis activator (erastin) on the one hand and CRY and the MAPK inhibitor on the other was followed by a significant abrogation of the effect of CRY on PCOS. The gene discussed is CRYL1; the disease is polycystic ovary syndrome.